Searchable abstracts of presentations at key conferences in endocrinology

ea0029p59 | Adrenal cortex | ICEECE2012

The effects of the acute administration of alprazolam, a benzodiazepine, in patients with subclinical Cushing’s syndrome

Berardelli R. , Karamouzis I. , Marinazzo E. , Picu A. , D'Angelo V. , Ghigo E. , Arvat E. , Giordano R.

Subclinical Cushing’s syndrome (SCS) is a status of altered hypothalamo-pituitary-adrenal (HPA)-axis secretion in the absence of the classical signs or symptoms of overt cortisol excess. Among the various tests used for the diagnosis of SCS, the 1-mg dexamethasone test (DST) is the most used. Alprazolam (ALP), a benzodiazepine activating GABAergic receptors, possesses clear centrally-mediated inhibitory effects on ACTH and cortisol secretion in normal subjects, while it d...

ea0029p1116 | Neuroendocrinology | ICEECE2012

Effects of mineralocorticoid agonists and antagonists on survival, proliferation and differentiation of adult rat hippocampal progenitor cells

Gesmundo I. , Gargantini E. , Settanni F. , Ghigo E. , Arvat E. , Granata R.

Introduction: Hippocampus is a key area in the brain and influences the neuroendocrine functions, especially the hypothalamo–pituitary–adrenal (HPA) axis that is mainly regulated by corticotrophin-releasing hormone (CRH), vasopressin (ADH) and glucocorticoid (GC). This feed-back action is mediated by both glucocorticoid (GRs) and mineralocorticoid (MRs) receptors. GRs are distributed throughout the brain, but mostly in hypothalamic neurons, while the MRs highest expr...

ea0029p1143 | Neuroendocrinology | ICEECE2012

Basal and stimulated GH secretion in active cushing’s syndrome and 2 years after remission

Picu A. , D'Angelo V. , Karamouzis I. , Berardelli R. , Marinazzo E. , Fussotto B. , Zichi C. , Giordano R. , Ghigo E. , Arvat E.

Impaired GH secretion occurs in Cushing’s syndrome (CS), reflecting hypothalamic and pituitary alterations, without IGF-I impairment. Obesity is known to blunt GH release, leading to BMI-related tests for GHD. Evaluation of GH in CS after remission is difficult, due to chronic previous hypercortisolism and persistent overweight. Aim of this study was to evaluate in 22 patients with Cushing’s syndrome (16 Cushing disease, CD, 6 adrenal adenomas, CS) GH response to GHR...

ea0011p599 | Neuroendocrinology and behaviour | ECE2006

Sensitivity and specificity of different provocative tests for the diagnosis of secondary hypoadrenalism in patients with hypothalamo-pituitary disorders

Picu A , Giordano R , Bonelli L , Balbo M , Pellegrino M , Berardelli R , Corneli G , Gasco V , Ghigo E , Arvat E

Insulin tolerance test (ITT) is considered the golden standard test to evaluate HPA axis in suspected hypopituitarism. Low dose (1 μg) ACTH1–24 short stimulation test (LDSST) and metyrapone are often used when ITT is contraindicated. The diagnostic reliability of LDSST is, however, controversial, as even this dose has been considered supramaximal, while very low ACTH doses have been suggested more reliable to assess the adrenal sensitivity. Thus, in...

ea0029p1081 | Neuroendocrinology | ICEECE2012

Wrist actigraphy detects sleep disorders in patients with Cushing's syndrome

Angelo V D' , Balbo M. , Beccuti G. , Berardelli R. , Karamouzis I. , Picu A. , Marinazzo E. , Fussotto B. , Zichi C. , Giordano R. , Ghigo E. , Arvat E.

Interrelationships between HPA axis and sleep architecture are well documented and increased glucocorticoid levels seem associated with quantitative and qualitative sleep disruptions. The knowledge about sleep parameters in chronic hypercortisolism in humans is scanty. Our aim was to evaluate sleep efficiency in patients with Cushing’s syndrome (CS) at time of diagnosis, without ongoing specific therapy, using wrist actigraphy, a methodology that provides good estimations...

ea0029p52 | Adrenal cortex | ICEECE2012

Efficacy of long-term treatment with retinoic acid in patients with Cushing’s disease

Giraldi F. Pecori , Ambrogio A. , Andrioli M. , Sanguin F. , Karamouzis I. , Corsello S. , Scaroni C. , Arvat E. , Pontecorvi A. , Cavagnini F.

Cushing’s disease, i.e. cortisol excess due to an ACTH-secreting pituitary adenoma, is a rare disorder with considerable morbidity and mortality. Current therapeutic strategies include pituitary surgery, radiation, adrenalectomy and medical treatment with steroidogenesis inhibitors, as drugs aimed at the pituitary adenoma are as yet under investigation. Experimental data showed that retinoic acid restrains ACTH secretion by tumoral corticotrophes thus we decided to evalua...